Legal & General Group Plc Purchases 174,360 Shares of Amgen, Inc. (AMGN)

Share on StockTwits

Legal & General Group Plc raised its position in Amgen, Inc. (NASDAQ:AMGN) by 5.7% in the 4th quarter, HoldingsChannel reports. The fund owned 3,241,580 shares of the medical research company’s stock after purchasing an additional 174,360 shares during the period. Legal & General Group Plc’s holdings in Amgen were worth $631,039,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of AMGN. Blue Fin Capital Inc. boosted its holdings in shares of Amgen by 10.0% in the 3rd quarter. Blue Fin Capital Inc. now owns 7,449 shares of the medical research company’s stock valued at $1,544,000 after buying an additional 677 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Amgen by 6.5% in the 3rd quarter. Macquarie Group Ltd. now owns 168,607 shares of the medical research company’s stock valued at $34,952,000 after buying an additional 10,237 shares in the last quarter. Kentucky Retirement Systems bought a new stake in shares of Amgen in the 3rd quarter valued at about $7,108,000. Neuberger Berman Group LLC boosted its holdings in shares of Amgen by 3.9% in the 3rd quarter. Neuberger Berman Group LLC now owns 154,783 shares of the medical research company’s stock valued at $32,085,000 after buying an additional 5,836 shares in the last quarter. Finally, B. Riley Wealth Management Inc. bought a new stake in shares of Amgen in the 3rd quarter valued at about $296,000. 79.18% of the stock is owned by hedge funds and other institutional investors.

AMGN has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a “neutral” rating and issued a price target on shares of Amgen in a report on Monday, January 14th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, January 14th. Cowen restated a “buy” rating and issued a $234.00 price target on shares of Amgen in a report on Tuesday, February 26th. Cantor Fitzgerald restated a “hold” rating and issued a $221.00 price target on shares of Amgen in a report on Monday, April 1st. Finally, Mizuho set a $208.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus target price of $209.11.

Shares of Amgen stock opened at $177.47 on Friday. The company has a market capitalization of $109.31 billion, a P/E ratio of 12.32, a P/E/G ratio of 2.17 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a 52 week low of $165.22 and a 52 week high of $210.19.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same period last year, the firm posted $2.89 EPS. Analysts expect that Amgen, Inc. will post 13.96 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.

In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total value of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 6,000 shares of company stock valued at $1,144,120 over the last ninety days. 0.27% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Legal & General Group Plc Purchases 174,360 Shares of Amgen, Inc. (AMGN)” was first published by Zolmax and is the property of of Zolmax. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://zolmax.com/investing/legal-general-group-plc-purchases-174360-shares-of-amgen-inc-amgn/3051968.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Portfolio Manager

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Plexus Corp.  Shares Sold by New York State Teachers Retirement System
Plexus Corp. Shares Sold by New York State Teachers Retirement System
Brookfield Property Reit Inc  Holdings Boosted by Sumitomo Mitsui Asset Management Company LTD
Brookfield Property Reit Inc Holdings Boosted by Sumitomo Mitsui Asset Management Company LTD
Zacks: Chaparral Energy Inc  Receives Consensus Recommendation of “Strong Buy” from Brokerages
Zacks: Chaparral Energy Inc Receives Consensus Recommendation of “Strong Buy” from Brokerages
Kora Network Token  Achieves Market Cap of $114,120.00
Kora Network Token Achieves Market Cap of $114,120.00
EagleX  Hits One Day Volume of $14.00
EagleX Hits One Day Volume of $14.00
Raymond James & Associates Buys 17,577 Shares of Invesco S&P International Developed Low Volatility ETF
Raymond James & Associates Buys 17,577 Shares of Invesco S&P International Developed Low Volatility ETF


 
© 2006-2019 Zolmax.